• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
In conclusion, this review has concisely summarized the current rare adverse events related and unrelated to BNT162b2, arguably for the first time in sufficient depth, to better communicate vaccine safety to the public.PMID:35891231 | DOI:10.3390/vaccines10071067
Source: Herpes - July 27, 2022 Category: Infectious Diseases Authors: Shin-Jie Yong Alice Halim Michael Halim Abbas Al Mutair Saad Alhumaid Jehad Al-Sihati Hawra Albayat Mohammed Alsaeed Mohammed Garout Reyouf Al Azmi Noor Aldakheel Abeer N Alshukairi Hani A Al Ali Adel A Almoumen Ali A Rabaan Source Type: research

Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a low...
Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research